Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg trims Kooth target price after H1 update

(Sharecast News) - Analysts at Berenberg lowered their target price on mental health services firm Kooth from 300p to 260p on Tuesday following the group's first-half results earlier in the morning. Kooth noted that it expects FY25 revenues and adjusted underlying earnings to be in line with current consensus expectations on a constant currency basis. This will mean that, on a reported basis, Kooth actually expects FY25 revenues to be 2-3% below current consensus expectations of £66.8m and its FY25 adjusted EBITDA to be 6-8% below expectations of £10.2m.

As a result, Berenberg reduced its FY25, FY26 and FY27 estimates for revenue by 4%, 4% and 5%, respectively, and for adjusted EBITDA by 5%, 3% and 6%, respectively.

However, the German bank, which has a 'buy' rating on the stock, said this implies "a significant margin improvement" in H2, as Kooth reduces its marketing investment.

It also pointed out that user registrations in California were now above 130,000, while the company noted that it will further expand its service offering in an evolution of its existing strategy to drive more sustainable growth.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.